Melphalan’s protein associations were highly distinct from those of bortezomib (Extended Data Fig. 7e), with increased efficacy in myeloma cells with high expression levels of integrin B2 (ITGB2) and E3 ubiquitin-protein ligase TRIP12, among others (Extended Data Fig. 7f). Here, TRIP12 is linked to plasma cell myeloma.